Benzoylpaeoniflorin promote cholesterol efflux by enhancing ABCA1 expression
CHEN Xiaojia1 TANG Wanze2 MA Weilie1 DING Hang1 ZHANG Zhizhen1
1.School of Basic Medicine, Guangdong Medical University, Guangdong Province, Dongguan 523808, China;
2.Department of Spine Surgery, Shenzhen People′s Hospital Shenzhen Institute for Orthopaedic Research, Guangdong Province, Shenzhen 518020, China
Abstract：Objective To investigate the effect of Benzoylpaeoniflorin (BP) on cholesterol efflux from THP-1 cells. Methods The experiment was divided into ac-LDL group, apoA-1 group and apoA-1+BP group. The model of foam cells was established by adding 160 nmol/L phorbol-1-myristate-13-acetate (PMA) for 24 h in THP-1 cells, followed by 50 μg/mL acetylated low-density lipoprotein (ac-LDL). The foam cells cholesterol efflux rate was determined using liquid scintillation counting, the contents of total cholesterol of foam cells were observed by enzymatic reaction method. adenosine triphosphate binding cassette transporter A1(ABCA1) mRNA expression was detected by quantitative polymerase chain reaction (qPCR). The expression of ABCA1, sterol regulated original binding proteins（SREBPs）and Liver X receptor alpha (LXRα) were analyzed by Western blot. Results THP-1 cell model was successfully established. Cholesterol efflux of foam cells in apoA-1+BP group was higher than that in apoA-1 group, and the difference was highly statistically significant (P < 0.01). The total cholesterol content of foam cells in apoA-1+BP group were lower than those in apoA-1 group, and difference was highly statistically significant (P < 0.01). The mRNA and protein levels of ABCA1 in apoA-1+BP group were higher than those in apoA-1 group, and the difference was statistically significant (P < 0.05 or P < 0.01). The expression levels of LXRα in apoA-1+BP group were higher than those in apoA-1 group, and the difference was highly statistically significant (P < 0.01). The SREBP1 and SREBP2 expression levels in apoA-1+BP group were lower than those in apoA-1 group, and the difference was highly statistically significant (P < 0.01). Conclusion BP can promote cholesterol efflux through the LXRα-ABCA1 pathway.
[1] 陈伟伟，高润霖，刘力生，等.《中国心血管病报告2017》概要[J].中国循环杂志，2018，33（11）：1-8.
[2] Varghese C，Onuma O，Johnson W，et al. Organizational update：World Health Organization [J]. Stroke，2017，48（12）：e341-e342.
[3] Kingwell BA，Chapman MJ，Kontush A，et al. HDL-targeted therapies：progress，failures and future [J]. Nat Rev Drug Discov，2014，13（6）：445-464.
[4] Siddiqi HK，Kiss D，Rader D. HDL-cholesterol and cardiovascular disease：rethinking our approach [J]. Curr Opin Cardiol，2015，30（5）：536-542.
[5] Shimizu T，Miura SI，Tanigawa H，et al. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet [J]. Arterioscl Throm Vas Biol，2014，34（10）：2246-2253.
[6] Morgan JM，Llera-Moya MDL，Capuzzi DM. Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux [J]. J Clin Lipidol，2007，1（6）：614-619.
[7] Qiao L，Chen W. Atheroprotective effects and molecular targets of bioactive compounds from traditional Chinese medicine [J]. Pharmacol Res，2018，135：212-229.
[8] Hutchins PM，Heinecke JW. Cholesterol efflux capacity，macrophage reverse cholesterol transport and cardioprotective HDL [J]. Curr Opin Lipidol，2015，26（5）：388-393.
[9] Mei X，Atkinson D. Lipid-free apolipoprotein A-I structure：insights into HDL formation and atherosclerosis development [J]. Arch Med Res，2015，46（5）：351-360.
[10] Shimano H，Sato R. SREBP-regulated lipid metabolism：convergent physiology-divergent pathophysiology [J]. Nat Rev Endocrinol，2017，13（12）：710-730.
[11] Guo S，Li Y，Yi H. Cholesterol homeostasis and Liver X receptor（LXR）in atherosclerosis [J]. Cardiovasc Hematol Disord Drug Targets，2018，18（1）：27-33.
[12] Talbot CPJ，Plat J，Ritsch A，et al. Determinants of cholesterol efflux capacity in humans [J]. Prog Lipid Res，2018， 69：21-32.
[13] 吴金雄.白芍、赤芍化学成分与活血功效的比较研究[D].广州：广州中医药大学，2012.
[14] 王巧，刘荣霞，毕开顺，等.HPLC法测定白芍总苷胶囊中芍药内酯苷、芍药苷和苯甲酰芍药苷[J].中草药，2005（11）：1630-1632.
[15] 刘月丽，吕俊华.白芍总苷的降血脂、抗氧化作用及其对脂肪肝的防治研究[J].海南医学院学报，2012，18（2）：158-161.
[16] 唐菀泽，马卫列，丁航，等.氧化芍药苷对泡沫细胞胆固醇流出的影响[J].中国现代医学杂志，2017，27（16）：6-11.
[17] Wan YJ，An D，Cai Y，et al. Hepatocyte-Specific Mutation Establishes Retinoid X Receptor alpha as a Heterodimeric Integrator of Multiple Physiological Processes in the Liver [J]. Mol Cell Biol，2000，20（12）：4436-4444.
[18] Kellner-Weibel G，Luke SJ，Rothblat GH. Cytotoxic cellular cholesterol is selectively removed by apoA-I via ABCA1 [J]. Atherosclerosis，2003，171（2）：235-243.
[19] Van Eck M. ATP-binding cassette transporter A1：key player in cardiovascular and metabolic disease at local and systemic level [J]. Curr Opin Lipidol，2014，25（4）：297-303.
[20] Hoang MH，Jia Y，Mok B，et al. Kaempferol ameliorates symptoms of metabolic syndrome by regulating activities of liver X receptor-β [J]. J Nutr Biochem，2015，26（8）：868-875.
[21] Tang JJ，Li JG，Qi W，et al. Inhibition of SREBP by a small molecule，betulin，improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques [J]. Cell Metab，2011，13（1）：44-56.
[22] Ma W，Ding H，Gong X，et al. Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels [J]. Atherosclerosis，2015， 239（2）：566-570.
2020, Vol. 17 
京公网安备 11010502046598号